Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PROK with free AI briefings, catalyst countdowns, and dilution alerts.

PROK · ProKidney Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$210M Cash on Hand
15.4mo Cash Runway
Follow PROK by email Get an email when PROK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PROK, unsubscribe in one click. Privacy

📣 What PROK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Rilparencel Type 2 Diabetes Mellitus Phase 3 · NCT05286853 Withdrawn
Renal Autologous Cell Therapy (REACT) Type 2 Diabetes Mellitus Phase 3 · NCT05099770 Active not recruiting
Neo-Kidney Augment Chronic Kidney Disease Phase 2 · NCT02525263 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PROK holds $210M in cash and short-term investments (as of Jun 30, 2026) and burns about $41M/quarter from operations, an estimated runway of 15.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PROK files for a raise →

Get the full PROK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PROK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.